Rein et lupus : données réc... - Société Française de Rhumatologie

2002;11:273–7.
[4] Sabbaga J, Pankewycz OG, Luft V, Schwartz RS, Madaio MP. Crossreactivity distinguishes serum and nephritogenic anti-DNA
antibodies in human lupus from their natural counterparts in normal serum. J Autoimmun 1990;3:215–35.
[5] Kramers C, Hylkema NM, Van Bruggen MCJ, Van de Lagemaat R, Dijkman HB, Assmann KJ, et al. Anti-nucleosome antibodies
complexed to nucleosome antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest
1994;94:568–77.
[6] Vlachoyiannopoulos PG, Karassa FB, Karakostas KX, Drosos AA, Moutsopoulos HM. Systemic lupus erythematosus in Greece.
Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 1993;2:303–12.
[7] Seligman VA, Suarez C, Lum R, Inda SE, Lin D, Li H, et al. The Fcgamma receptor IIIA-158F allele is a major risk factor for the
development of lupus nephritis among Caucasians but not non- Caucasians. Arthritis Rheum 2001;44:618–25.
[8] Seligman VA, Lum RF, Olson JL, Li H, Criswell LA. Demographic differences in the development of lupus nephritis: a retrospective
analysis. Am J Med 2002;112:726–69.
[9] Fremeaux-BacchiV, Noel LH, Schifferli JA. No lupus nephritis in the absence of antiC1q autoantibodies? Nephrol Dial Transplant
2002;17: 2041–3.
[10] Vlachoyiannopoulos PG, Kanellopoulos P, Tektonidou M, Moutsopoulos HM. Renal involvement in antiphospholipid syndrome.
Nephrol Dial Transplant 2001;16(Suppl 6):60–2.
[11] Weening JJ, D’Agati V, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic
lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241–50.
[12] Daugas E, Nochy D, Huong du LT, Duhaut P, Beaufils H, CaudwellV, et al. Antiphospholipid syndrome nephropathy in systemic
lupus erythematosus. J Am Soc Nephrol 2002;13:42–52.
[13] Austin 3rd HA, Klippel JH, Balow JE, Le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis : controlled trial of
prednisone and cytotoxic drugs. N Engl J Med 1986;314:614–9.
[14] Boumpas DT,Austin 3rd HA,Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse
methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741–5.
[15] Gourley MF, Austin 3rd HA, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide alone or
in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549–57.
[16] Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus
pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern
Med 2001; 135:248–57.
[17] Boumpas DT,Austin 3rd HA,Vaughan EM,Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with
systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366–9.
[18] Ciruelo E, De la Cruz J, Lopez I, Gomez-Reino JJ. Cumulative rate of relapse of lupus nephritis after successful treatment with
cyclophosphamide. Arthritis Rheum 1996;39:2028–34.
[19] Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, et al. Remission, relapse and re-remission of
proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57: 258–64.
[20] Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, et al. Immunosuppressive therapy in lupus
nephritis. The Euro-lupus nephritis trial, a randomized trial of lowdose versus high-dose intraveinous cyclophosphamide. Arthritis
Rheum 2002;46:2121–31.
[21] Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl
J Med 2004;350:971–80.
[22] Chan TM, Li FK, Tang CS,Wong RW, Fang GX, JiYL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative
lupus nephritis. N Engl J Med 2000;343:1156–62.
[23] Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, StrandV, et al. LJP 394 for the prevention of renal flare in
patients with systemic lupus erythematosus: results from a randomized, doubleblind, placebo-controlled study. Arthritis Rheum
2003;48:442–54.
[24] Mercadal L, Montcel ST, Nochy D, Queffeulou G, Piette JC, Isnard- Bagnis C, et al. Factors affecting outcome and prognosis in
membranous lupus nephropathy. Nephrol Dial Transplant 2002;17:1771–8.
[25] Huong DL, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus. A
study of 180 patients from a single center. Medicine 1999;78:148–66.
[26] Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans.
Glomerular Disease Collaborative Network. Kidney Int 1997;51:1188–95.
[27] Barr RG, Seliger S, Appel GB, Zuniga R, D’Agati V, Salmon J, et al. Prognosis in proliferative lupus nephritis: the role of socioeconomic
status and race/ethnicity. Nephrol Dial Transplant 2003;18:2039–46.
[28] Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G, et al. Antiphospholipid antibodies are associated with an increased
risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004;43:28–36.
[29] Mojcik CF, Klippel JH. End-stage renal disease and systemic lupus erythematosus. Am J Med 1996;101:100–7. A. Karras, F.
Martinez / Revue du Rhumatisme 72 (2005) 162–167 167
© SFR - A. Karras, F. Martinez / Revue du Rhumatisme 72 (2005) 162–167